# Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct02340117/  
OnCo record `nct02340117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by SynerGene Therapeutics, Inc., active and no longer recruiting.

## Summary

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT02340117 by SynerGene Therapeutics, Inc., with 28 participants enrolled, started 2015-01 and due to reach its primary completion in 2026-12. Interventions recorded: SGT-53, nab-paclitaxel and Gemcitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02340117
- Phase: 2
- Setting: Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer
- Sponsor: SynerGene Therapeutics, Inc.
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT02340117: https://clinicaltrials.gov/study/NCT02340117

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct02340117.json